CD22 and Siglec‐G: B‐cell inhibitory receptors with distinct functions
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Summary: Siglecs (sialic acid‐binding immunoglobulin‐like lectins) are sialic acid‐binding proteins, which are expressed on many cell types of the immune system. B cells express two members of the Siglec family, CD22 (Siglec‐2) and Siglec‐G, both of which have been shown to inhibit B‐cell signaling. CD22 recruits the tyrosine phosphatase Src homology 2 domain‐containing phosphatase 1 (SHP‐1) to immunoreceptor tyrosine‐based inhibitory motifs (ITIMs) and inhibits B‐cell receptor (BCR)‐induced Ca 2+ signaling on normal B cells. CD22 interacts specifically with ligands carrying α2–6‐linked sialic acids. Interaction with these ligands in cis regulates the association of CD22 with the BCR and thereby modulates the inhibitory function of CD22. Interaction of CD22 to ligands in trans can regulate both B‐cell migration as well as the BCR signaling threshold. Siglec‐G is a recently identified protein with an inhibitory function restricted to a B‐cell subset, the B1 cells. Siglec‐G inhibits Ca 2+ signaling specifically in these cells. In addition, it controls the cellular expansion and antibody secretion of B1 cells. Thus, both Siglecs modulate BCR signaling on different B‐cell populations in a mutually exclusive fashion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CD24 and Siglec-10 Selectively Repress Tissue Damage–Induced Immune Responses
Chen, G.-Y., Tang, J., Zheng, P., & Liu, Y. (2009) · Science · doi:10.1126/science.1168988 · Cited by 786 · cited 1×
“A recent study reported a sialic acid-dependent interaction of the glycosylated cell surface molecule CD24 with Siglec-G and soluble high mobility group box 1 protein (HMGB1) in a tri-molecular complex on other cells than B cells (114).”
Background
Cited by
Jackson, H. J., Rafiq, S., & Brentjens, R. J. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.36 · Cited by 613
Multifarious roles of sialic acids in immunity
Varki, A., & Gagneux, P. (2012) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2012.06517.x · Cited by 611
Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia
Haso, W., Lee, D. W., Shah, N. N., Stetler-Stevenson, M., Yuan, C. M., Pastan, I. H., Dimitrov, D. S., Morgan, R. A., FitzGerald, D. J., Barrett, D. M., et al. (2013) · Blood · doi:10.1182/blood-2012-06-438002 · Cited by 572
Antibody–Drug Conjugates (ADCs): current and future biopharmaceuticals
Wang, R., Hu, B., Pan, Z., Mo, C., Zhao, X., Liu, G., Hou, P., Cui, Q., Xu, Z., Wang, W., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01704-3 · Cited by 285
B‐cell targeted therapies in human autoimmune diseases: an updated perspective
Townsend, M. J., Monroe, J. G., & Chan, A. C. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00945.x · Cited by 232
Metadata
- Authors
- Nitschke, L.
- Venue
- Immunological Reviews
- Publisher
- Wiley
- Published
- 2009-06-29
- Volume
- 230
- Issue
- 1
- Pages
- 128-143
- ISSN
- 0105-2896 (ISSN-L)
- 1600-065X
- OpenAlex
- W2033799256
- Cited by
- 147
- References
- 1
- FWCI
- 0.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CD22 and Siglec‐G: B‐cell inhibitory receptors with distinct functions. https://app.cochat.ai/papers/10.1111/j.1600-065x.2009.00801.x
- The paper
- Nitschke, L. (2009). CD22 and Siglec‐G: B‐cell inhibitory receptors with distinct functions. Immunological Reviews. https://doi.org/10.1111/j.1600-065x.2009.00801.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.